Switch theme
Sign up to access all valuation multiples
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
2012
64
LTM Revenue $11.2M
Last FY EBITDA -$51.7M
$47.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aclaris Therapeutics has a last 12-month revenue (LTM) of $11.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aclaris Therapeutics achieved revenue of $18.7M and an EBITDA of -$51.7M.
Aclaris Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aclaris Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.2M | XXX | $18.7M | XXX | XXX | XXX |
| Gross Profit | $9.6M | XXX | $3.3M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 17% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$51.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -276% | XXX | XXX | XXX |
| EBIT | -$94.3M | XXX | -$52.5M | XXX | XXX | XXX |
| EBIT Margin | -842% | XXX | -281% | XXX | XXX | XXX |
| Net Profit | -$94.6M | XXX | -$132M | XXX | XXX | XXX |
| Net Margin | -845% | XXX | -705% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Aclaris Therapeutics's stock price is $2.
Aclaris Therapeutics has current market cap of $166M, and EV of $47.0M.
See Aclaris Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $47.0M | $166M | XXX | XXX | XXX | XXX | $-1.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Aclaris Therapeutics has market cap of $166M and EV of $47.0M.
Aclaris Therapeutics's trades at 2.5x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Aclaris Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aclaris Therapeutics has a P/E ratio of -1.8x.
See valuation multiples for Aclaris Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV (current) | $47.0M | XXX | $47.0M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -0.5x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAclaris Therapeutics's last 12 month revenue growth is -50%
Aclaris Therapeutics's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.9M for the same period.
Aclaris Therapeutics's rule of 40 is -419% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aclaris Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aclaris Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -50% | XXX | -46% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -276% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -419% | XXX | -326% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 179% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 298% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aclaris Therapeutics acquired XXX companies to date.
Last acquisition by Aclaris Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Aclaris Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aclaris Therapeutics founded? | Aclaris Therapeutics was founded in 2012. |
| Where is Aclaris Therapeutics headquartered? | Aclaris Therapeutics is headquartered in United States of America. |
| How many employees does Aclaris Therapeutics have? | As of today, Aclaris Therapeutics has 64 employees. |
| Who is the CEO of Aclaris Therapeutics? | Aclaris Therapeutics's CEO is Dr. Neal Walker, D.O.. |
| Is Aclaris Therapeutics publicy listed? | Yes, Aclaris Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Aclaris Therapeutics? | Aclaris Therapeutics trades under ACRS ticker. |
| When did Aclaris Therapeutics go public? | Aclaris Therapeutics went public in 2015. |
| Who are competitors of Aclaris Therapeutics? | Similar companies to Aclaris Therapeutics include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Aclaris Therapeutics? | Aclaris Therapeutics's current market cap is $166M |
| What is the current revenue of Aclaris Therapeutics? | Aclaris Therapeutics's last 12 months revenue is $11.2M. |
| What is the current revenue growth of Aclaris Therapeutics? | Aclaris Therapeutics revenue growth (NTM/LTM) is -50%. |
| What is the current EV/Revenue multiple of Aclaris Therapeutics? | Current revenue multiple of Aclaris Therapeutics is 4.2x. |
| Is Aclaris Therapeutics profitable? | Yes, Aclaris Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
